Last reviewed · How we verify

NCT04628377

Prognostic Implication of Angiography-Derived IMR in STEMI Patients

Completed Last updated 12 April 2023
What this trial tests

trial testing Angiography-drived Index of Microcirculatory Resistance in Acute ST-segment Elevation Myocardial Infarction in 333 participants. Completed in 1 April 2023.

Timeline
26 May 2003
Primary endpoint
1 March 2023
1 April 2023

Quick facts

Lead sponsorSamsung Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment333
Start date26 May 2003
Primary completion1 March 2023
Estimated completion1 April 2023

Drugs / interventions tested

Conditions studied

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Acute ST-segment Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of STEMI patients. Previous study presented that index of microcirculatory resistance (IMR) in culprit vessel of STEMI patients showed significant association with the risk of cardiac death or heart failure admission. Recent technical development enabled angiographic derivation of IMR without pressure wire, hyperemic agents, or theromdilution method. In this regard, the current study will evaluate prognostic implication of angiography-derived IMR in STEMI patients who were successfully revascularized.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Functional Coronary Angiography-Derived Index of Microcirculatory Resistance in Patients With ST-Segment Elevation Myocardial Infarction.
    Choi KH, Dai N, Li Y, Kim J, et al · · 2021 · cited 115× · PMID 34353599 · DOI 10.1016/j.jcin.2021.05.027

Verify or expand the search:

Other trials of Angiography-drived Index of Microcirculatory Resistance

Trials testing the same drug.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04628377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing